The FDA’s new support of a single study approach has drawn much discussion, raising questions as to whether conducting just one confirmatory study is a risky position for sponsors to take. In this blog, Andrew Garrett,...
-
ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach
Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials.
-
Forbes names ICON in list of Best Employers in America for Women
ICON recognised as top employer for women in anonymous survey of 75,000 employees.
-
ICON shareholders vote in favour of all resolutions at its Annual General Meeting
Dublin, Ireland, July 22, 2020
-
ICON reports first quarter 2020 results
Reported revenue of $715.1 million representing a 6.0% YoY increase or 6.5% on a constant currency basis. Net business wins of $867 million; a book to bill of 1.21.
-
ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row
ICON recognised for specialised services offering across product development lifecycle, winning five awards overall.
-
ICON signs new service agreement with Pfizer
Agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.
-
ICON launches the Coronavirus Observatory
The Coronavirus Observatory applies powerful AI analysis and data visualisation to COVID-19 news and social media, providing updates on the latest vaccine trials.
-
ICON acquires MedPass International
Acquisition expands ICON’s global Medical Device and Diagnostic Research Services
-
ICON reports fourth quarter and full year 2019 results
ICON reports Q4 & 2019 results. Full year reported revenue was $2,806 million. This represents a year on year increase of 8.1% or 9.6% on a constant currency basis
-
ICON wins Best Contract Research Organisation – Full-Service Providers at the 15th Annual Scrip Awards 2019
ICON awarded for capabilities and innovations in successful drug development and patient recruitment.
